

Subject/Title: ASI ASO SLIDE TEST		Doc#: 6004-300 CLSI
Effective Date: 06/18	Supersedes Revision/Date: 08/12	Revision: 06/18
Supersedes Procedure #	Prepared by: ASI	Date Adopted:

Review Date:		
Revision Date:		
Signature:		

For in vitro diagnostic use

<u>Catalog Number</u>	<u>Kit Size</u>
300025	25 Tests
300050	50 Tests
300100	100 Tests
3001000	1000 Tests

CPT Code: 86060

- 1 **INTENDED USE:** The **ASI ASO Slide Test** is a latex slide agglutination assay for the qualitative and semi quantitative detection of antistreptolysin-O (ASO) antibodies in human serum. No initial dilution of patient samples is required for this test. These materials are intended to be acquired, possessed and used only by health professionals.
- 2 **SUMMARY AND EXPLANATION:** Streptolysin-O is one of the two hemolytic exotoxins produced by group A streptococci. When infected, a patient will produce an antibody, antistreptolysin-O, that is detectable in serum. The **ASI ASO Slide Test** provides a means of measuring these antibodies in serum and can assist in the determination of the severity of the infection.
- 3 **PRINCIPLE OF THE PROCEDURE:** The ASO LATEX REAGENT is a stabilized and buffered suspension of polystyrene latex particles that have been coated with streptolysin-O.¹ When the LATEX REAGENT is mixed with serum containing antibodies to streptolysin-O, agglutination occurs. The LATEX REAGENT has been adjusted so that agglutination will take place only when the level of antibodies to streptolysin-O is greater than 200 IU/ml, a level determined by epidemiological and clinical studies to be indicative of disease.²
- 4 **REAGENTS**
 - 4.1 LATEX REAGENT - Suspended inert latex particles coated with streptolysin-O, with 0.1% sodium azide as preservative.
 - 4.2 CONTROLS (Reactive, Nonreactive) - Human serum or defibrinated plasma (liquid), with 0.1% sodium azide as preservative.
- 5 **WARNINGS AND PRECAUTIONS**

For In Vitro Diagnostic Use

 - 5.1 ASI ASO LATEX REAGENT and CONTROLS contain sodium azide. Azides in contact with lead and copper plumbing may react to form highly explosive metal azides. When disposing of reagents containing azide, flush down the drain with large quantities of water to prevent azide build-up.

5.2 ASI ASO CONTROLS contain human serum or plasma which has been tested at the donor level for HBsAg and for HIV-1, HIV-2 and HCV antibodies and found to be nonreactive. As no known test offers complete assurance that infectious agents are absent, the CONTROLS should be considered potentially infectious and universal precautions should be used. The CDC/NIH Health Manual "Biosafety in Microbiological and Biomedical Laboratories" describes how these materials should be handled in accordance with Good Laboratory Practice.

5.3 Do not pipet by mouth.

5.4 Do not smoke, eat, drink or apply cosmetics in areas where plasma/serum samples are handled.

5.5 Any cuts, abrasions or other skin lesions should be suitably protected.

6 HANDLING AND PROCEDURAL NOTES

6.1 In order to obtain reliable and consistent results, the instructions in the package insert must be strictly followed. Do not modify the handling and storage conditions for reagents or samples.

6.2 Do not use past the expiration date indicated on the kit.

6.3 Do not interchange components of one kit with those of another kit.

7 **STORAGE INSTRUCTIONS:** Store all reagents at 2-8°C in an upright position when not in use. Do not freeze reagents. Pipets and cards do not require refrigeration.

8 INDICATIONS OF DETERIORATION

8.1 Turbidity or precipitation in controls is indicative of deterioration and the component should not be used.

8.2 Bacterial contamination of reagents or specimens may cause false positive results.

9 SPECIMEN COLLECTION AND STORAGE

9.1 Use only serum that is free from contamination. Test samples should not be heat-inactivated.

9.2 It is preferable to test samples on the day of their collection. If samples cannot be tested immediately, maintain them in their original tubes at 2-8°C and test within 48 hours.

9.3 Serum samples stored longer than 48 hours should be stored at -20°C or below until testing. Avoid repeated freezing and thawing of specimens.

9.4 If necessary before testing, centrifuge the specimens at a force sufficient to sediment cellular components.

9.5 Samples to be sent out for testing should be placed on ice packs and packaged like any other biohazardous material that could potentially transmit infection.

PERFORMANCE OF THE TEST

10 MATERIALS PROVIDED:

	25 Tests	50 Tests	100 Tests	1000 Tests
ASO LATEX REAGENT	1.0 ml	2.0 ml	2 x 2.0 ml	20 x 2.0 ml
REACTIVE CONTROL	0.5 ml	1.0 ml	1.0 ml	10 x 1.0 ml
NONREACTIVE CONTROL	0.5 ml	1.0 ml	1.0 ml	10 x 1.0 ml
0.03 ml Disposable Stirrer Pipets	25	50	100	1000
Disposable Test Cards (6-well)	5	9	17	170

11 ADDITIONAL MATERIALS REQUIRED

- 11.1 Timing device
- 11.2 13 x 75 mm test tubes
- 11.3 Volumetric pipet to deliver 0.25 ml
- 11.4 Saline (0.9% NaCl solution)
- 11.5 Mechanical rotator (optional)

12 TEST PROCEDURE

12.1 PREPARATION FOR THE ASSAY

- 12.1.1 Allow all reagents and samples to warm to room temperature (20-30°C) before use. Remove reagents from foam holders. Do not heat reagents in a water bath.
- 12.1.2 All reagents are ready for use as supplied. Gently mix the reagents before use; avoid foaming.
- 12.1.3 Gently mix the LATEX REAGENT before each use to ensure homogeneity.

12.2 ASSAY PROTOCOL - QUALITATIVE

- 12.2.1 Using the stirrer pipets, deliver one free-falling drop (0.03 ml) of each serum sample onto a separate circle on the test card. Use a fresh stirrer pipet for each sample. When using the stirrer pipet, keep it in a vertical position to ensure accurate delivery. Repeat by adding one free-falling drop of REACTIVE or NONREACTIVE CONTROL from the dropper vials supplied. Note the location of each sample by using the numbers located below and to the left of each circle.
- 12.2.2 Expel the contents of the LATEX REAGENT dropper and refill. Add one drop of the reagent to each serum specimen and to each control.
- 12.2.3 Using the flat end of the stirrer pipets, mix each specimen and control serum with the LATEX REAGENT, in a circular manner, over the entire area in the circles of the card.
- 12.2.4 Gently tilt and rotate the card for two (2) minutes and observe for agglutination. All test results should be compared to both REACTIVE and NONREACTIVE CONTROLS.

12.3 ASSAY PROTOCOL - SEMIQUANTITATIVE

12.3.1 Prepare serial dilutions of patient serum, in SALINE SOLUTION, in test tubes as follows:

<u>Tube</u>	<u>Dilution</u>	<u>Composition</u>
1	1:2	0.25 ml of serum + 0.25 ml of saline solution. Mix.
2	1:4	0.25 ml from tube 1 + 0.25 ml of saline solution. Mix.
3	1:8	0.25 ml from tube 2 + 0.25 ml of saline solution. Mix.
4	1:16	0.25 ml from tube 3 + 0.25 ml of saline solution. Mix.
5	1:32	0.25 ml from tube 4 + 0.25 ml of saline solution. Mix.

Testing on additional dilutions should be performed as needed.

12.3.2 Using each dilution as a separate test specimen, apply the samples to the card as described in step 1 of the Qualitative Assay Protocol and proceed with steps 2 through 4 of the Qualitative Assay Protocol. Include undiluted sample if not tested previously on that day with the same lot of LATEX REAGENT.

13 QUALITY CONTROL: Quality control requirements must be performed in accordance with applicable local, state and/or federal regulations or accreditation requirements and your laboratory's standard Quality Control Procedures. Controls with graded reactivity should be included. If control samples do not yield the expected response, the assay should be considered invalid and the assay repeated. If the repeat assay does not elicit the expected results for the control samples, discontinue use of the kit and contact ASI Technical Support at (800) 654-0146.

14 INTERPRETATION OF RESULTS

14.1 INTERPRETATION OF RESULTS- QUALITATIVE

Agglutination indicates an ASO concentration of greater than or equal to 200 IU/ml in the serum sample. Sera that elicit a positive result should be retested and titered using the Semiquantitative Assay Protocol.

14.2 INTERPRETATION OF RESULTS- SEMIQUANTITATIVE

The highest dilution in which visible agglutination occurs is considered the endpoint titer. The corresponding ASO concentration (in IU/ml) is calculated as the product of the endpoint dilution factor and the assay cut-off value as shown in the following table. For example, if the endpoint dilution is 1:8, the corresponding ASO serum concentration would be 8 x 200, or 1600 IU/ml.

Dilution	ASO IU/ml (in NEAT specimen)
NEAT*	200
1:2	400
1:4	800
1:8	1600
1:16	3200
1:32	6400

*NEAT = undiluted

15 LIMITATIONS OF THE PROCEDURE

- 15.1 Because extremely high levels of antibodies might affect the degree of agglutination, positive samples should be reassayed using the semiquantitative procedure.
- 15.2 Contaminated, lipemic, or grossly hemolyzed sera should not be used because of the possibility of nonspecific results.
- 15.3 Plasma samples should not be used because of the possibility of nonspecific results.
- 15.4 Temperature of the reagents and samples is crucial to test outcome. It should be between 20° and 30°C.
- 15.5 Reaction times longer than specified might cause false positive results due to a drying effect.
- 15.6 Elevated serum levels of beta-lipoprotein and cholesterol might suppress a rise in ASO titer.
- 15.7 Penicillin or other antibiotic therapy might suppress a rise in ASO titer.
- 15.8 In accord with all diagnostic methods, a final diagnosis should not be made on the result of a single test, but should be based on a correlation of test results with other clinical findings.

16 EXPECTED VALUES

It is common to detect ASO antibodies in most of the population with titers varying according to geographical location and age distribution. Increased ASO titers may be associated with rheumatic fever and glomerulonephritis.³ An ASO titer of more than 200 IU/ml might be indicative of streptococcal infection. The titer should be monitored over a time period of 4 to 6 weeks.

17 REFERENCES

1. Halbert SP. 1963. *Ann NY Acad Sci*, **103**:1027-1051.
2. Klein GL. 1971. *App Microbiol*, **21**:999.
3. Klein GC. 1976. *Manual of Clinical Immunology*, American Society for Microbiology, Washington DC, p. 264.

TECHNICAL INFORMATION: (801) 489-8911 or (800) 654-0146